4893 Noile-Immune Biotech
- 172
- +1+0.58%
Noile-Immune Biotech News
Noile-Immune Biotech: (Correction) Partial Corrections to the “Notice Concerning the Recording of Non-operating Income”
Noile-Immune Biotech: Notice Concerning the Recording of Non-Operating Profit
Noile-Immune Biotech: Notice regarding publication of earnings forecasts
Noile-Immune Biotech: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Noile-Immune Biotech: Correction Confirmation Form
Noile-Immune Biotech: Revised Semi-Annual Report - Term 10 (2024/01/01 to 2024/12/31)
Noile-Immune Biotech: (Correction) Partial Corrections to the “Notice Concerning Prioritization of Our Drug Discovery Pipeline and Associated Changes in the Use of Funds Raised at the Time of Listing”
Noile-Immune Biotech: Notice regarding a business alliance with Takara Bio Co., Ltd. for the development of NIB103
Noile-Immune Biotech: Semi-Annual Report - Term 10 (2024/01/01 - 2024/12/31)
Noile-Immune Biotech: Confirmatory letter.
Noile-Immune Biotech: 2nd quarter (interim) financial report for the fiscal year ending December 2024 [Japan Standard] (non-consolidated)
Noile-Immune Biotech: Change Report
Noile-Immune Biotech: Change report.
Noile-Immune Biotech: Announcements of individual stocks regarding the re-prioritization of our in-house drug development pipeline and changes in the use of funds raised at the time of listing.
Noile-Immune Biotech: Regarding the return of NIB102 and NIB103 to Takeda Pharmaceutical.
Noile-Immune Biotech: Change report.
Noile-Immune Biotech: Change Report
Noile-Immune Biotech: Confirmation letter
Noile-Immune Biotech: Quarterly Report - 10th Quarter 1st Quarter (2024/01/01 - 2024/03/31)
Noile-Immune Biotech: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Analysis
Price Target
No Data
No Data